Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers

被引:19
|
作者
Tushar, Tewari [1 ]
Vinod, Thomas [1 ]
Rajan, Sundaram [1 ]
Shashindran, Chanolean [1 ]
Adithan, Chandrasekaran [1 ]
机构
[1] JIPMER, Dept Pharmacol, Pondicherry 605006, India
关键词
D O I
10.1111/j.1742-7843.2006.00039.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Honey is a common food supplement but not many studies have studied honey and drug interaction. This study investigates the influence of 7 days of honey administration on the activity of CYP3A4, CYP2D6 and CYP2CI9 drug-metabolizing enzymes in healthy volunteers by using appropriate biomarker and probe drugs. A within-group pharmacokinetic study was done in 12 healthy volunteers. Urine samples (0-8 hr) were collected after administration of 30 mg of oral dextromethorphan (probe drug for CYP2D6) for analysis of dextromethorphan and dextrorphan. A plasma sample (4 hr) was collected after administration of 200 mg of oral proguanil (probe drug for CYP2C19) for the analysis of proguanil and cycloguanil. Urine samples (0-24 hr) were collected for the analysis of 6 beta-hydroxycortisol (biomarker for CYP3A4). The volunteers were administered honey for 7 days. Subsequently blood and urine samples were collected after drug dosing as before. These samples were analysed for drug and metabolite concentrations in urine and plasma using high performance liquid chromatography method. Seven days of honey administration resulted in statistically significant increase in 24-hr urinary excretion of 6 beta-hydroxyeortisol. However, the metabolic ratios of dextromethorphan and proguanil were not significantly altered after 7 days of honey administration. Honey obtained from Western Ghats of southern India may induce CYP3A4 enzyme activity but not CYP2D6 and CYP2C19 enzyme activities.
引用
收藏
页码:269 / 272
页数:4
相关论文
共 50 条
  • [21] Effect of rivoceranib administered as 200 mg once daily on the pharmacokinetics of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 substrates
    Jang, Seong
    Wei, Xiaohui
    Meng, Xianzhang
    Reitano, Joseph
    Urity, Vinoo
    Park, Cheol Hee
    Strickland, Bill
    Lee, Grace
    Nguyen, David
    CANCER RESEARCH, 2024, 84 (07)
  • [22] Mechanism-based inactivation (MBI) of recombinant CYP2C19 and CYP3A4 but not human liver microsomal CYP2C19 and CYP3A4 by nortriptyline
    Polasek, Thomas M.
    Miners, John O.
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 234 - 234
  • [23] Allele and Genotype Frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese Populations
    Zuo, Liang Jin
    Guo, Tao
    Xia, Dong Ya
    Jia, Li Hui
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (02) : 102 - 108
  • [24] Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers
    Brit S. Rohr
    Evelyn Krohmer
    Kathrin I. Foerster
    Jürgen Burhenne
    Martin Schulz
    Antje Blank
    Gerd Mikus
    Walter E. Haefeli
    Clinical Pharmacokinetics, 2024, 63 : 469 - 481
  • [25] Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers
    Rohr, Brit S.
    Krohmer, Evelyn
    Foerster, Kathrin I.
    Burhenne, Juergen
    Schulz, Martin
    Blank, Antje
    Mikus, Gerd
    Haefeli, Walter E.
    CLINICAL PHARMACOKINETICS, 2024, 63 (04) : 469 - 481
  • [26] The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population
    Liou, Ya-Huei
    Lin, Chien-Ting
    Wu, Ying-Jye
    Wu, Lawrence Shih-Hsin
    JOURNAL OF HUMAN GENETICS, 2006, 51 (10) : 857 - 863
  • [27] GENETIC POLYMORPHISMS OF CYTOCHROME P450 (CYP) 2C9, CYP2C19, CYP2D6, CYP3A4, AND CYP3A5 IN A KORSIAN POPULATION
    Lim, Y.
    Kim, E.
    Lee, Y.
    Cha, E.
    Jung, H.
    Kim, J.
    Lee, S.
    Shin, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S61 - S61
  • [28] Hydroxychloroquine is metabolized by CYP2D6, CYP3A4 and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A4 in vitro
    Paludetto, M.
    Kurkela, M.
    Kahma, H.
    Backman, J.
    Niemi, M.
    Filppula, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S78 - S78
  • [29] Comparison of Paeoniflorin and Albiflorin on Human CYP3A4 and CYP2D6
    Gao, Li-Na
    Zhang, Ye
    Cui, Yuan-Lu
    Akinyi, Olunga Mary
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 2015
  • [30] The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population
    Ya-Huei Liou
    Chien-Ting Lin
    Ying-Jye Wu
    Lawrence Shih-Hsin Wu
    Journal of Human Genetics, 2006, 51